President Trump is scheduled to be in Philadelphia on Tuesday, September 15, 2020 at The National Constitution Center (NCC) in the Independence Mall area. Increased police presence is anticipated in Center City throughout Tuesday afternoon and evening. Please allow extra time if you are going to Wills Eye. Please be advised of area street closures to vehicles beginning at 1:00PM on Tuesday 9/15. Pedestrian access will also be limited in the area. This is subject to change and area restrictions, which could widen, will be lifted once the President departs the NCC. There are also demonstrations planned for Tuesday 9/15 around Independence Mall as well as City Avenue.

Wills Eye Clinical Trials – Glaucoma

RESEARCH_Secondary Page Header
Age Related Macular Degeneration
Advancing Science • Fostering Collaboration • Inspiring Innovation
Age Related Macular Degeneration

Glaucoma: A 28-Day, Open-label, multi-site, pilot study evaluating the safety and intraocular lowering effect of delivering Travoprost using a punctal plug delivery system (Evolute®) in subjects with elevated intraocular pressure.

PI: Aakriti Shukla, MD

In an open-label study, we are evaluating replacing the use of a daily instilled ocular hypotensive drop with a punctal plug delivery system to deliver an eye pressure-lowering drug to the eye for 28 days.

Patients with a history of open-angle glaucoma or ocular hypertension (high eye pressure without glaucoma damage) who meet all study inclusion/exclusion criteria will be asked to discontinue their current hypotensive medication for six weeks. At the end of six weeks, if a subject still meets all study inclusion/exclusion criteria, a drug-releasing punctal plug will be inserted into each eye.

The study will involve a total of five visits (baseline, week 6, the day after, day 7 and day 28 after being inserted with a punctal plug). Subjects will be compensated for their participation in the study.

Clinical Study Coordinator: Jeanne Molineaux,